-
Cartesian Therapeutics NasdaqGM:RNAC Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Location: 7495 New Horizon Way, Frederick, MD, 21703, United States | Website: https://www.cartesiantherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
93.17M
Cash
180.4M
Avg Qtr Burn
-7.716M
Short % of Float
26.82%
Insider Ownership
77.58%
Institutional Own.
25.63%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SEL-212 (Pegadricase) Details Chronic refractory gout, Arthritis | BLA Submission | |
Descartes-08 Details Myasthenia gravis | Phase 3 Data readout | |
Descartes-08 Details Systemic lupus erythematosus | Phase 2 Data readout | |
Descartes-08 Details Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis | Phase 2 Initiation | |
Descartes-15 Details Multiple myeloma | Phase 1 Data readout | |
SEL-302 (MMA-101 + ImmTOR) Details Genetic disorder, Methylmalonic acidemia | Failed Discontinued |